Limited Offer
Save 50% on book bundles
Immediately download your ebook while waiting for your print delivery. No promo code needed.
Resistance to Anti-CD20 Antibodies and Approaches for Their Reversal
- 1st Edition, Volume 2 - August 30, 2023
- Editor: William Chi Shing Cho
- Language: English
- Hardback ISBN:9 7 8 - 0 - 4 4 3 - 1 9 2 0 0 - 5
- eBook ISBN:9 7 8 - 0 - 4 4 3 - 1 9 2 0 1 - 2
Resistance to Anti-CD20 Antibodies and Approaches for Their Reversal presents in-depth content written by international experts in the study of resistance to anti-CD20 antibodie… Read more
Purchase options
Institutional subscription on ScienceDirect
Request a sales quoteResistance to Anti-CD20 Antibodies and Approaches for Their Reversal presents in-depth content written by international experts in the study of resistance to anti-CD20 antibodies and approaches for their reversal. Anti-CD20 antibodies are used to achieve B cell depletion and are developed to treat B cell proliferative disorders, including non-Hodgkin’s lymphoma and chronic lymphocytic leukemia. In the past two decades, anti-CD20 antibodies have revolutionized the treatment of all B cell malignancies, however, there are patients that fail to respond to initial therapy or relapse sooner. This book explores new and existing avenues surrounding Anti-CD20 antibodies.
In recent years, several next-generation anti-CD20 therapies have been developed but predicting and reversing resistance is still a challenging task. These areas are being actively studied as they represent a potential to improve anti-CD20 therapies and are discussed thoroughly in the book.
It is a valuable resource for researchers, students and member of the biomedical and medical fields who want to learn more about resistance to anti-CD20 antibodies and their reversal.
• Presentation of current research, critical analyses, in-depth literature reviews, and the latest clinical reports on anti-CD20 antibody treatment
• Discussion of recent developments of anti-CD20 antibodies in cancer and noncancer diseases treatment, possible resistance mechanisms and their reversals, as well as the exciting therapeutic opportunities offered by anti-CD20 antibodies in combination with chemotherapy or other treatment modalities
• Utilization of a number of diagrams to visually illustrate complex content and plenty of tables to summarize important information
• Discussion of recent developments of anti-CD20 antibodies in cancer and noncancer diseases treatment, possible resistance mechanisms and their reversals, as well as the exciting therapeutic opportunities offered by anti-CD20 antibodies in combination with chemotherapy or other treatment modalities
• Utilization of a number of diagrams to visually illustrate complex content and plenty of tables to summarize important information
Clinicians, oncologists, rheumatologists, neurologists, nephrologists, translational scientists, pharmaceutical scientists, pharmacists and graduate students
- Cover image
- Title page
- Table of Contents
- Front Matter
- Copyright
- Cover Image Insert
- Aims and Scope of Series “Breaking Tolerance to Antibody-Targeted Therapies”
- About the Series Editor
- Aims and Scope of the Volume
- About the Volume Editor
- Preface
- Contributors
- Part I: Therapeutic anti-CD20 antibodies against cancers and escape
- Chapter 1: Therapeutic antibodies against cancer—A step toward the treatment
- Abstract
- Introduction
- Search strategy and selection criteria
- Structural format of therapeutic antibodies and their mechanism
- Designing of chimeric, humanized, and human antibodies
- CD20 as a potential target, the resistance of therapeutic antibody against it, and the importance of computational role
- What do we now know about anti-CD20 and its importance?
- How do cancer cells become resistant to mAbs after receiving treatment?
- Resistance issue with anti-CD20 therapies and potential strategies for reversing their effect
- Computational techniques to design the therapeutic antibody
- Availability of antibody databases
- Advantages and disadvantages of therapeutic antibodies
- Possible side effects
- Current limitations with production cost
- Future
- Predictive biomarkers—A therapeutic response against cancer
- Conclusions
- References
- Chapter 2: Anti-CD20 antibody treatment for B-cell malignancies
- Abstract
- Conflict of interest
- Introduction
- B-cell malignancies
- Mechanism of B-cell carcinogenesis/lymphomagenesis
- Anti-CD20 antibodies
- Future perspectives
- Conclusions
- References
- Chapter 3: Anti-CD20 antibody treatment for diffuse large B cell lymphoma: Genetic alterations and signaling pathways
- Abstract
- Conflict of interest
- Introduction
- Mechanisms of rituximab
- Genetic alterations and molecular mechanisms
- Other possible mechanisms of rituximab resistance
- Conclusions
- References
- Chapter 4: Non-Hodgkin lymphoma treated with anti-CD20 antibody-based immunochemotherapy
- Abstract
- Conflict of interest
- Introduction
- Clinical experience
- Anti-CD20 resistance
- New approaches of B-cell-directed therapy: Beyond rituximab
- Conclusions and future perspectives
- References
- Chapter 5: Targeted therapies for follicular lymphoma
- Abstract
- Introduction
- Lenalidomide
- PI3K inhibitors
- BTK inhibitors
- BCL-2 inhibitor
- EZH2 inhibitor
- Antibody-drug conjugates
- Bispecific antibody
- Chimeric antigen receptor T-cell therapy
- Conclusions
- Future perspectives
- References
- Chapter 6: Treatment of relapsed follicular lymphoma
- Abstract
- Conflict of interest
- Background
- Overview of treatment at relapse: Objectives of treatment
- Treatment in challenging situations: POD24
- Treatment in challenging situations: Histological transformation
- Consolidation of the response: Maintenance
- Consolidation of the response: Stem cell transplantation (SCT) and cellular therapy (CT)
- Conclusions and future perspective
- References
- Chapter 7: New monoclonal antibodies for the treatment of acute lymphoblastic leukemia
- Abstract
- Introduction
- Approved antibody-based therapies for B-ALL
- Mechanisms of resistance to licensed antibody therapies
- Investigational therapies
- Conclusions
- References
- Chapter 8: Clinical relevance and therapeutic implications of CD20 expression in Hodgkin's lymphoma
- Abstract
- Introduction
- Etiopathogenesis of classical Hodgkin’s lymphoma (cHL) and the role of the CD20 marker
- Epstein-Barr virus (EBV) infection and HL
- Classical Hodgkin’s lymphoma (cHL)
- Pathophysiology
- Impact of the CD20+ expression on the evolution and prognosis of HL
- Standard approach for HL treatment
- Clinical efficacy of anti-CD20 therapy on HL
- Immunogenicity, safety, and resistance mechanism to anti-CD20 antibodies
- Future perspectives
- Conclusions
- References
- Part II: Resistance and affinity determination of anti-CD20 antibodies
- Chapter 9: Therapeutic options for rituximab-resistant patients
- Abstract
- Introduction
- Mechanisms of rituximab resistance
- Therapeutic options after rituximab resistance
- Conclusions and perspectives
- References
- Chapter 10: Mechanisms of resistance to anti-CD20 antibodies in lymphoid malignancies
- Abstract
- Introduction
- Factors influencing anti-CD20 mAb activity/resistance
- Future perspectives
- Conclusions
- References
- Chapter 11: Kinetic exclusion assay using cellular membranes for affinity determination of anti-CD20 antibody
- Abstract
- Conflict of interest
- Anti-CD20 antibodies and biology
- Binding characterization technologies
- Important controls for analytical validity in KinExA experiments
- Analysis of soluble protein targets
- Analysis of integral membrane protein targets
- Determination of the free CBP concentration in the binding of soluble and membrane protein targets
- Conclusions
- References
- Part III: Therapeutic anti-CD20 antibodies against noncancer diseases
- Chapter 12: Clinical efficacy of anti-CD20 antibodies in autoimmune diseases
- Abstract
- Conflict of interest
- Introduction
- Cellular and molecular mechanisms of autoimmunity
- List of FDA-approved anti-CD20 antibodies, off-label anti-CD20 antibodies, and clinical trials on anti-CD20 antibodies in autoimmune diseases
- Mechanisms of action of anti-CD20 antibodies and their effects in autoimmune diseases
- Efficacy of anti-CD20 antibodies therapy in autoimmune diseases
- Efficacy of anti-CD20 antibodies therapy for immune dysregulation disorders
- Side effects and prerequisites related to anti-CD20 antibodies therapy in autoimmune diseases
- New developments and challenges
- Conclusions
- References
- Chapter 13: B-cell depletion with obinutuzumab for the treatment of proliferative lupus nephritis
- Abstract
- Conflict of interest
- Introduction
- Treatment of LN
- The role of B-cells in SLE and LN pathogenesis and targets for treatment
- B-cell-depleting therapies for proliferative LN
- The need for type II B-cell-depleting agents
- Obinutuzumab treatment in proliferative LN
- Conclusions
- References
- Chapter 14: Anti-CD20 antibodies in glomerular diseases, their resistance and reversal approaches
- Abstract
- Statement of ethics
- Funding
- Prior presentations
- Data availability statement
- Introduction
- Lupus nephritis
- ANCA-associated vasculitis
- Membranous nephropathy
- Minimal change disease
- Focal segmental glomerulosclerosis
- Cryoglobulinemia
- Thrombotic microangiopathy
- Kidney transplant
- Resistance to anti-CD20 mAb
- Approaches to reversal
- Conclusions
- References
- Chapter 15: Adverse events following rituximab therapy in pemphigus patients
- Abstract
- Introduction
- Paradoxical worsening
- Resistance to RTX
- Future perspectives
- References
- Chapter 16: Immune monitoring of patients treated with anti-CD20 therapeutic monoclonals for autoimmune disorders
- Abstract
- Introduction
- Functional and phenotypic development of B cells
- CD20 as a marker of mature B cells
- Mechanism of action of rituximab and other anti-CD20 therapeutic antibodies
- The rationale for B cell depletion treatment in autoimmune disorders
- Circulating plasmablasts as effectors in autoimmune disorders
- Immune monitoring of anti-CD20 therapies in autoimmune disorders
- Monitoring the expected peripheral B cell patterns during anti-CD20 treatment
- The varied rituximab schedules in autoimmune disorders: The risk of overimmunosuppression
- Resistance to rituximab and escape phenomena in autoimmune disorders treated with anti-CD20
- Limitations and open issues in the immune monitoring of autoimmune disorders treated with anti-CD20
- Concluding remarks and future perspectives
- Appendix 1
- References
- Chapter 17: Clinical efficacy of anti-CD20 antibodies in neurological and neuromuscular diseases
- Abstract
- Introduction
- Physiological and pathophysiological roles of CD20+ lymphocytes
- Perspectives on the development of anti-CD20 mAbs
- Clinic implications of CD20 as a therapeutic target in neurological and neuromuscular diseases
- Conclusions
- References
- Chapter 18: Reversal of resistance to anti-CD20 antibody therapies: Conclusions and future perspectives
- Conflict of interest
- Introduction
- Therapeutic anti-CD20 antibodies against cancers and escape
- Resistance and affinity determination of anti-CD20 antibodies
- Therapeutic anti-CD20 antibodies against noncancer diseases
- Future perspectives
- References
- Index
- No. of pages: 442
- Language: English
- Edition: 1
- Volume: 2
- Published: August 30, 2023
- Imprint: Academic Press
- Hardback ISBN: 9780443192005
- eBook ISBN: 9780443192012
WC
William Chi Shing Cho
William C.S. Cho, PhD, RCMP, FHKIMLS, FHKSMDS, Chartered Scientist (UK), FIBMS (UK). Department of Clinical Oncology, Queen Elizabeth Hospital, Hong Kong SAR, China. Dr. Cho’s primary research interests focus on cancer research to discover biomarkers for cancer diagnosis, treatment prediction, and prognosis. As a seasoned researcher, Dr. Cho has conducted cancer research using molecular biology, proteomics, genomics, immunology, bioinformatics, and next-generation sequencing technologies. Dr. Cho has published more than 600 peer-reviewed papers (Lancet, Lancet Oncology, Annals of Oncology, Lancet Gastroenterology & Hepatology, Advanced Science, Nature Communications, PNAS, Molecular Cancer, Journal of Thoracic Oncology, Journal of the National Cancer Institute, Journal of Extracellular Vesicles, Clinical Cancer Research, Clinical Chemistry, Theranostics, etc.) covering cancer biomarkers, proteomics, noncoding RNA, traditional Chinese medicine, and dozens of books (including An Omics Perspective on Cancer Research, MicroRNAs in Cancer Translational Research, Drug Repurposing in Cancer Therapy: Approaches and Applications, Supportive Cancer Care with Chinese Medicine, etc.). The cumulative impact factor of journals exceeds 4500, and the papers have been cited >25,000 times. Dr. Cho is listed among the top 2% of the most influential scientists in the world. In addition, Dr. Cho has served as a research grant reviewer for many international research funds, including the Hope Funds for Cancer Research (United States), Cancer Research (United Kingdom), National Medical Research Council (Singapore), etc.
Affiliations and expertise
Queen Elizabeth Hospital, Hong Kong, ChinaRead Resistance to Anti-CD20 Antibodies and Approaches for Their Reversal on ScienceDirect